Document:

Exhibit 10.1

 

MYR GROUP INC.

 

PERFORMANCE SHARES AWARD AGREEMENT

 

(Executive Officer)

 

This AGREEMENT (this
“Agreement”) is made as of March 22, 2019, by and between MYR Group Inc., a Delaware corporation (the “Company”),
and [             ] (the “Participant”).

 

		1.	Grant of Performance Shares. Pursuant to the MYR Group Inc. 2017 Long-Term Incentive Plan (the “Plan”) and
subject to the terms and conditions thereof and the terms and conditions hereinafter set forth, the Company has granted to the
Participant, as of March 22, 2019 (the “Date of Grant”), [            ] target Performance Shares, a percentage of which may be
earned in accordance with the terms of this Agreement and contingent on the Company’s Return On Invested Capital (“ROIC”)
over the ROIC Performance Period (as defined below) (such target amount, the “ROIC Target Performance Shares”), and
[             ] target Performance Shares, a percentage of which may be earned in accordance with the terms of this Agreement and contingent
on the Company’s relative Total Stockholder Return (“TSR”) over the TSR Performance Period (as defined below)
(such target amount, the “TSR Target Performance Shares”). The Performance Shares are not intended to be a Qualified-Performance
Based Award under the Plan.

 

		2.	Earning of Target Performance Shares.

 

		(a)	Performance Measure: The Participant’s right to receive all of, any portion of, or more than, the number of ROIC
Target Performance Shares or TSR Target Performance Shares generally will be contingent upon the achievement of specified levels
of the Company’s ROIC and relative TSR, as set forth in the “Statement of Performance Goals” established by the
Committee in connection with the Awards granted by this Agreement, and will be measured over each fiscal year in the period from
January 1, 2019 through December 31, 2021 for ROIC performance (the “ROIC Performance Period”) and the arithmetic average
of the ROIC for the ROIC Performance Period, which shall be calculated by dividing the sum of the Company’s ROIC for each
fiscal year in the ROIC Performance Period by the number of years in the ROIC Performance Period (the “Three-Year Average”),
and the Date of Grant through December 31, 2021 for TSR performance (the “TSR Performance Period” and together with
the ROIC Performance Period, the “Performance Periods”).

 

		(b)	Below Threshold:

 

		(i)	ROIC: If, upon the conclusion of the ROIC Performance Period, ROIC for any fiscal year in the ROIC Performance Period
or the Three-Year Average ROIC for the ROIC Performance Period falls below the threshold level, as set forth in the ROIC Performance
Matrix contained in the Statement of Performance Goals, no Performance Shares for ROIC performance shall become earned for that
fiscal year and/or the Three-Year Average, as applicable.

 

    	 	1	 

     

    

 

		(ii)	TSR: If, upon conclusion of the TSR Performance Period, the Company’s relative TSR for the TSR Performance Period
falls below the 25th percentile of TSR for the TSR Peer Group Companies (as defined below), no Performance Shares for
TSR performance shall become earned.

 

		(c)	Threshold:

 

		(i)	ROIC: If, upon the conclusion of the ROIC Performance Period, ROIC for any fiscal year in the ROIC Performance Period
and/or the Three-Year Average ROIC for the ROIC Performance Period equals the threshold level, as set forth in the ROIC Performance
Matrix contained in the Statement of Performance Goals, 10% of the ROIC Target Performance Shares shall be earned for each such
fiscal year and 20% of the ROIC Target Performance Shares shall be earned for the Three Year Average ROIC, with a fractional share
from the total earned ROIC Target Performance Shares rounded down to the next whole share.

 

		(ii)	TSR: If, upon conclusion of the TSR Performance Period, the Company’s relative TSR for the TSR Performance Period
is at the 25th percentile of TSR for the TSR Peer Group Companies, 25% of the TSR Target Performance Shares shall become
earned, with a fractional share rounded down to the next whole share.

 

		(d)	Between Threshold and Target:

 

		(i)	ROIC: If, upon the conclusion of the ROIC Performance Period, ROIC for any fiscal year in the ROIC Performance Period
and/or the Three-Year Average exceeds the threshold level, but is less than the target level, as set forth in the ROIC Performance
Matrix contained in the Statement of Performance Goals, the percentage of ROIC Target Performance Shares that shall become earned
shall be determined by the summation of the percentage of ROIC payout as determined by mathematical straight-line interpolation
of actual ROIC performance compared to the ROIC performance metrics for each such fiscal year multiplied times 20% and the Three
Year Average ROIC performance compared to the ROIC performance metrics multiplied times 40% between 50% (threshold) payout of the
ROIC Target Performance Shares and 100% (target) payout of the ROIC Target Performance Shares, with a fractional share from the
total earned ROIC Target Performance Shares rounded down to the next whole share.

 

		(ii)	TSR: If, upon the conclusion of the TSR Performance Period, the Company’s relative TSR exceeds the 25th
percentile, but is less than the 50th percentile of TSR of the TSR Peer Group Companies, the percentage of TSR Target
Performance Shares that shall become earned shall be determined by mathematical straight-line interpolation between 25% of the
TSR Target Performance Shares and 100% of the TSR Target Performance Shares, with a fractional share rounded down to the next whole
share.

 

    	 	2	 

     

    

 

		(e)	Target:

 

		(i)	ROIC: If, upon the conclusion of the ROIC Performance Period, ROIC for any fiscal year in the ROIC Performance Period
and/or the Three-Year Average equals the target level, as set forth in the ROIC Performance Matrix contained in the Statement of
Performance Goals, 20% of the ROIC Target Performance Shares shall be earned for each such fiscal year and 40% of the ROIC Target
Performance Shares shall be earned for the Three Year Average ROIC, with a fractional share from the total earned ROIC Target Performance
Shares rounded down to the next whole share.

 

		(ii)	TSR: If, upon conclusion of the TSR Performance Period, the Company’s relative TSR for the TSR Performance Period
is at the 50th percentile of TSR for the TSR Peer Group Companies, 100% of the TSR Target Performance Shares shall become
earned, with a fractional share rounded down to the next whole share.

 

		(f)	Between Target and Maximum:

 

		(i)	ROIC: If, upon the conclusion of the ROIC Performance Period, ROIC for any fiscal year in the ROIC Performance Period
and/or the Three-Year Average exceeds the target level, but is less than the maximum level, as set forth in the ROIC Performance
Matrix contained in the Statement of Performance Goals, the percentage of ROIC Target Performance Shares that shall become earned
shall be determined by the summation of the percentage of ROIC payout as determined by mathematical straight-line interpolation
of actual ROIC performance compared to the ROIC performance metrics for each such fiscal year multiplied times 20% and the Three
Year Average ROIC performance compared to the ROIC performance metrics multiplied times 40% between 100% (target) payout of the
ROIC Target Performance Shares and 200% (maximum) payout of the ROIC Target Performance Shares, with a fractional share from the
total earned ROIC Target Performance Shares rounded down to the next whole share.

 

		(ii)	TSR: If, upon the conclusion of the TSR Performance Period, the Company’s relative TSR exceeds the 50th
percentile, but is less than the 75th percentile of TSR for the TSR Peer Group Companies, the percentage of TSR Target
Performance Shares that shall become earned shall be determined by mathematical straight-line interpolation between 100% of the
TSR Target Performance Shares and 200% of the TSR Target Performance Shares, with a fractional share rounded down to the next whole
share.

 

    	 	3	 

     

    

 

		(g)	Equals or Exceeds Maximum:

 

		(i)	ROIC: If, upon the conclusion of the ROIC Performance Period, ROIC for any fiscal year in the ROIC Performance Period
and/or the Three-Year Average equals or exceeds the maximum level, as set forth in the ROIC Performance Matrix contained in the
Statement of Performance Goals, 40% of the ROIC Target Performance Shares shall be earned for each such fiscal year and 80% of
the ROIC Target Performance Shares shall be earned for the Three Year Average ROIC, with a fractional share from the total earned
ROIC Target Performance Shares rounded down to the next whole share.

 

		(ii)	TSR: If, upon conclusion of the TSR Performance Period, the Company’s relative TSR for the TSR Performance Period
equals or exceeds the 75th percentile of TSR for the TSR Peer Group Companies, 200% of the TSR Target Performance Shares
shall become earned, with a fractional share rounded down to the next whole share.

 

		(h)	Conditions; Determination of Earned Award: Except as otherwise provided herein, the Participant’s right to receive
any Performance Shares is contingent upon his or her remaining in the continuous employ of the Company or a Subsidiary through
the end of the Performance Periods. Following the Performance Periods, the Committee shall determine whether and to what extent
the goals relating to ROIC and TSR have been satisfied for the Performance Periods and shall determine the percent of ROIC Target
Performance Shares and TSR Target Performance Shares, if any, that may have become earned hereunder.

 

		(i)	Determination Regarding ROIC: ROIC for each fiscal year in the ROIC Performance Period is defined as net income plus
net interest net of taxes (net income plus net interest, less net interest times the effective tax rate), less dividends divided
by invested capital (funded debt less cash and marketable securities plus total stockholders’ equity) at the beginning of
each fiscal year,

 

	
         ROIC
	=	Net Income + (Net Interest x (1 – Tax Rate)) – Dividends
	Funded Debt – Cash and Marketable Securities + Total Stockholders’ Equity

 

with all financial measures as determined
from the Company’s consolidated financial statements for each year in the ROIC Performance Period, subject to any
adjustment as determined by the Committee.

 

		(j)	Determination Regarding TSR: At the end of the TSR Performance Period, the percentile rank of the Company’s TSR
in respect to the TSR of the TSR Peer Companies will be calculated. TSR with respect to the Company and each of the TSR Peer Companies
means the change in the fair market value of common stock of the Company and the TSR Peer Companies, assuming reinvestment of dividends,
over the TSR Performance Period. The measurement of change in fair market value over the Performance Period shall be based on the
average closing prices of the common stock for the last 20 trading days preceding the Date of Grant and the last 20 trading days
preceding the end of the TSR Performance Period (December 31, 2021), assuming reinvestment of dividends in common stock. Any TSR
Peer Company that is no longer publicly traded at any time during or at the end of the TSR Performance Period shall be excluded
from this calculation.

 

    	 	4	 

     

    

 

		(k)	TSR Peer Companies: The public companies against which the Company’s TSR performance will be compared (the “TSR
Peer Group Companies”) are identified in the Statement of Performance Goals.

 

		3.	Pro Rata Earning of Target Performance Shares.

 

		(a)	Termination without Cause or Good Reason, Death, Disability or Retirement: Notwithstanding Section 2(h), if,
during the Performance Period, but before the payment of any Performance Shares as set forth in Section 5, the Participant’s
employment is terminated without “Cause” or with “Good Reason” (as each term is defined in the Participant’s
current Employment Agreement with the Company, as may be amended from time to time (the “Employment Agreement”)), the
Participant dies or in the event of his “Disability” (as such term is defined in the Employment Agreement) while in
the employ of the Company or in the event of the retirement of the Participant after having attained “normal retirement age”
(as such term is defined in the Social Security Act of 1935, as amended), then the Participant shall be entitled to receive such
percent of the ROIC Target Performance Shares and TSR Target Performance Shares, if any, as is determined pursuant to Section
2 at the conclusion of the Performance Periods as if the Participant had remained in the continuous employ of the Company through
the end of the Performance Periods, based on the Company’s ROIC and TSR performance during the Performance Periods, prorated,
based on the number of whole months that the Participant was employed by the Company during the Performance Periods.

 

		(b)	Change in Control: Notwithstanding Section 2(h), if, during the Performance Periods, but before the payment of
any Performance Shares as set forth in Section 5, a Change in Control occurs while the Participant is an employee of the
Company, then the Participant shall be entitled to receive the number of ROIC Target Performance Shares and the number of TSR Target
Performance Shares set out in Section 1.

 

		4.	Forfeiture of Award. Except to the extent the Participant has earned the right to receive Performance Shares pursuant
to Section 2 or 3 hereof, the Participant’s right to receive Performance Shares shall be forfeited automatically
and without further notice on the date that the Participant ceases to be an employee of the Company or a Subsidiary prior to the
last day of the Performance Periods or, in the event that Section 3(b) applies, the date on which the Change in Control
occurs.

 

		5.	Payment of Performance Shares.

 

		(a)	Subject to Section 5(c), Performance Shares earned as provided in Section 2 or pursuant to Section 3(a) shall
be paid to the Participant or his or her executor or administrator, as the case may be, in shares of Common Stock in the calendar
year immediately following the close of the Performance Period to which the award relates, but in no event later than two and one-half
(2 1/2) months after the close of the Performance Period.

 

    	 	5	 

     

    

 

		(b)	The ROIC Target Performance Shares and TSR Target Performance Shares earned pursuant to Section 3(b) shall be paid to
the Participant in shares of Common Stock as soon as practicable following the Change in Control, but in no event later than two
and one-half (2 1/2) months following the end of the year in which the Change in Control occurs.

 

		(c)	Notwithstanding anything in this Agreement to the contrary, if the Participant is a “specified employee” as determined
pursuant to procedures adopted by the Company in compliance with Section 409A of the Code, the ROIC Target Performance Shares and
TSR Target Performance Shares become payable on the Participant’s “separation from service” with the Company
and its Subsidiaries within the meaning of Section 409A(a)(2)(A)(i) of the Code, and the amount payable hereunder constitutes a
“deferral of compensation” (within the meaning of Section 409A of the Code), then payment of the ROIC Target Performance
Shares and TSR Target Performance Shares shall be made on the earlier of the first day of the seventh month after the date of the
Participant’s “separation from service” with the Company and its Subsidiaries within the meaning of Section 409A(a)(2)(A)(i)
of the Code or the Participant’s death.

 

		6.	Transferability. Transferability shall be as set forth in the Plan.

 

		7.	No Employment Contract. Nothing contained in this Agreement shall (a) confer upon the Participant any right to be employed
by or remain employed by the Company, or (b) limit or affect in any manner the right of the Company to terminate the employment
of the Participant at any time.

 

		8.	Taxes and Withholding. To the extent that the Company is required to withhold any federal, state, local or foreign taxes
in connection with the payment of any Performance Shares, it shall be a condition to the payment of any Performance Shares that
the Participant shall pay such taxes by the Company’s retention of a portion of the shares of Common Stock otherwise payable
to the Participant. The shares so retained shall be credited against such withholding requirement at the Fair Market Value on the
date of such delivery. In no event, however, shall the Company accept shares for payment of taxes in excess of minimum required
tax withholding rates; therefore, the Participant agrees to a payroll deduction for the amount of the withholding requirement that
may be greater than the value of the whole number of shares retained for such purpose.

 

		9.	Rights of a Stockholder. The Participant shall not have any rights of a stockholder with respect to the Performance
Shares prior to the date such shares are earned.

 

		10.	Payment of Dividends. No dividends or dividend equivalents shall be accrued or earned with respect to any Performance
Shares until such Performance Shares are earned by the Participant as provided in this Agreement.

 

		11.	Adjustments. Notwithstanding any other provision hereof, the number of Performance Shares subject to this Agreement,
and the other terms and conditions of this award, are subject to mandatory adjustment as provided in Section 3.2 of the Plan.

 

    	 	6	 

     

    

 

		12.	Restrictive Covenants. If the Participant engages in any conduct in breach of any noncompetition, nonsolicitation or
confidentiality obligations to the Company under any agreement, policy or plan, then such conduct shall also be deemed to be a
breach of the terms of the Plan and this Agreement. Upon such breach, the Participant’s right to receive Performance Shares
covered by this Agreement shall be forfeited automatically and without further notice and to the extent that the Participant has
received shares of Common Stock pursuant to Section 5 within a period of 18 months prior to such breach, the Participant
shall be required to return to the Company, upon demand, such shares or the net proceeds of any sales. For purposes of this Section
12, net proceeds shall mean the net amount realized upon the disposition of the shares. Notwithstanding anything in this Agreement
to the contrary, nothing in this Agreement prevents the Participant from providing, without prior notice to the Company, information
to governmental authorities regarding possible legal violations or otherwise testifying or participating in any investigation or
proceeding by any governmental authorities regarding possible legal violations, and for purpose of clarity the Participant is not
prohibited from providing information voluntarily to the Securities and Exchange Commission pursuant to Section 21F of the Exchange
Act.

 

		13.	Recovery of Performance Shares. If (a) the Company restates any part of its financial statements for any fiscal year
or years covered by the Performance Periods due to material noncompliance with any financial reporting requirement under the U.S.
securities laws applicable to such fiscal year or years (a “Restatement”) and (b) the Committee determines that the
Participant is personally responsible for causing the Restatement as a result of the Participant’s personal misconduct or
any fraudulent activity on the part of the Participant, then the Committee has discretion to, based on applicable facts and circumstances
and subject to applicable law, cause the Company to recover all or any portion (but no more than 100%) of the shares of Common
Stock paid or payable to the Participant for the Performance Periods. The amount of any cash or shares recovered by the Company
under this Section 13 shall be limited to the amount by which such shares payment exceeded the amount that would have been
paid to or received by the Participant had the Company’s financial statements for the applicable restated fiscal year or
years been initially filed as restated, as reasonably determined by the Committee. Notwithstanding anything herein to the contrary,
the Participant’s consent shall not be required for an amendment to this Agreement that is deemed necessary by the Company
to ensure compliance with the Dodd-Frank Wall Street Reform and Consumer Protection Act (the “Dodd-Frank Act”) or any
regulations promulgated thereunder, including as a result of the implementation of any recoupment policy the Company adopts to
comply with the requirements set forth in the Dodd-Frank Act.

 

		14.	Relation to Plan. This Agreement is subject to the terms and conditions of the Plan. In the event of any inconsistency
between the provisions of this Agreement and the Plan, the Plan shall govern. The Committee acting pursuant to the Plan, as constituted
from time to time, shall, except as expressly provided otherwise herein or in the Plan, have the right to determine any questions
that arise and to exercise its discretionary authority under the Plan in connection with the grant of ROIC Target Performance Shares
and TSR Target Performance Shares.

 

		15.	Miscellaneous. All decisions or interpretations of the Committee with respect to any question arising under the Plan
or this Agreement shall be binding, conclusive and final. The waiver by the Company of any provision of this Agreement shall not
operate as or be construed to be a subsequent waiver of the same provision or of any other provision of this Agreement. The Participant
agrees to execute such other agreements, documents or assignments as may be necessary or desirable to effect the purposes of this
Agreement.

 

		16.	Capitalized Terms. All capitalized terms used in this Agreement that are not defined herein shall have the meanings
given them in the Plan or resolutions adopted by the Committee authorizing grants made under this Agreement, unless the context
clearly requires otherwise.

 

		17.	Section 409A of the Code. To the extent applicable, it is intended that this Agreement and the Plan comply with, or
be exempt from, the provisions of Section 409A of the Code. This Agreement and the Plan shall be administered in a manner consistent
with this intent, and any provision that would cause this Agreement or the Plan to fail to satisfy Section 409A of the Code shall
have no force or effect until amended to comply with Section 409A of the Code (which amendment may be retroactive to the extent
permitted by Section 409A of the Code and may be made by the Company without the consent of the Participant). Any reference in
this Agreement to Section 409A of the Code will also include any proposed, temporary or final regulations, or any other guidance,
promulgated with respect to such section by the U.S. Department of the Treasury or the Internal Revenue Service.

 

    	 	7	 

     

    

  

IN WITNESS WHEREOF,
the Company has caused this Agreement to be executed on its behalf by its duly authorized officer and the Participant has executed
this Agreement, as of the day and year first above written.

 

	 	MYR GROUP INC.
	 	 	 
	 	By:	
	 	 	Name:  Kenneth M. Hartwick
	 	 	Title:  Chairman of the Board

 

The undersigned Participant hereby acknowledges
receipt of an executed copy of this Agreement and accepts the right to receive any Performance Shares or other securities covered
hereby, subject to the terms and conditions of the Plan and the terms and conditions herein above set forth.

 

	 	 
	 	Participant
	 	 	 
	 	Date:	

 

    	 	8Exhibit

Exhibit 10.1

CVS CAREMARK CORPORATION

Change in Control Agreement for

Eva Boratto

CONFIDENTIAL    JULY 2010

	
				
	 
	 
	Page

	1.
	Definitions .................................................................................................................
	2
	

	2.
	Term of Agreement ...................................................................................................
	6
	

	3.
	Entitlement to Severance Benefit .............................................................................
	6
	

	4.
	Confidentiality; Cooperation with Regard to Litigation; Non-disparagement ............
	8
	

	5.
	Non-solicitation .........................................................................................................
	9
	

	6.
	Remedies .................................................................................................................
	10
	

	7.
	Effect of Agreement on Other Benefits and Obligations ...........................................
	10
	

	8.
	Not an Employment Agreement ...............................................................................
	10
	

	9.
	Resolution of Disputes .............................................................................................
	10
	

	10.
	Assignability; Binding Nature ....................................................................................
	10
	

	11.
	Representation .........................................................................................................
	11
	

	12.
	Entire Agreement ......................................................................................................
	11
	

	13.
	Amendment or Waiver, Code Section 409A .............................................................
	11
	

	14.
	Severability ...............................................................................................................
	11
	

	15.
	Survivorship ..............................................................................................................
	11
	

	16.
	Beneficiaries/References .........................................................................................
	12
	

	17.
	Governing Law/Jurisdiction ......................................................................................
	12
	

	18.
	Notices .....................................................................................................................
	12
	

	19.
	Headings ..................................................................................................................
	12
	

	20.
	Counterparts .............................................................................................................
	13
	

1

This Change in Control Agreement ("Agreement") is effective as of July 19, 2010 between CVS Pharmacy, Inc. ("CVS") and Eva Boratto (the "Executive").

WHEREAS, the Board of Directors (the "Board") of CVS Caremark Corporation ("CVS Caremark") believes it is necessary and desirable for the CVS Caremark and its Subsidiaries and affiliates (collectively, the "Company") to be able to rely upon Executive to continue serving in his or her position with the Company in the event of a pending or actual change in control of CVS Caremark;

WHEREAS, Executive is employed by a Subsidiary of CVS Caremark, and this Agreement shall not alter Executive's status as an employee at will;

NOW, THEREFORE, in consideration of the promises and mutual covenants contained herein and for other good and valuable consideration, the receipt of which is mutually acknowledged, CVS and Executive (individually a "Party" and together the "Parties) agree as follows:

		
	1.
	Definitions.

		
	a.
	"Base Salary" shall mean Executive's annual rate of base salary at the time of Executive's termination of employment or, if greater, as in effect immediately prior to a Change in Control.

		
	b.
	"Cause" shall exist if:

		
	i.
	Executive willfully and materially breaches Sections 4 or 5 of this Agreement;

		
	ii.
	Executive is convicted of a felony involving moral turpitude; or

		
	iii.
	Executive engages in conduct that constitutes willful gross neglect or willful gross misconduct in carrying out Executive's duties under this Agreement, resulting, in either case, in material harm to the financial condition or reputation of the Company.

For purposes of this Agreement an act or failure to act on Executive's part shall be considered "willful" if it was done or omitted to be done by Executive not in good faith, and shall not include any act or failure to act resulting from any incapacity of Executive. A termination for Cause shall not take effect absent compliance with the provisions of this paragraph. Executive shall be given written notice by the Company of its intention to terminate Executive's employment for Cause, such notice (A) to state in detail the particular act or acts or failure or failures to act that constitute the grounds on which the proposed termination for Cause is based and (B) to be given within 90 days of the Company's learning of such act or acts or failure or failures to act. Executive shall have 20 days after the date that such written notice has been given to Executive in which to cure such conduct, to extent such cure is possible. If Executive fails to cure such conduct, Executive shall then be entitled to a hearing before the Committee, or an officer or officers designated by the Committee, at which Executive is entitled to appear. Such hearing shall be held within 25 days of such notice to Executive, provided Executive requests such hearing within 10 days of the written notice from the Company of the intention to terminate Executive for Cause. If, within five days following such hearing, Executive is furnished written notice by the Committee confirming that, in its judgment, grounds for Cause on the basis of the original notice exist, Executive shall thereupon be terminated for Cause. Executive's right to cure in accordance with this provision applies only in the event of a Change in Control as defined in Section 1(c) below and does not alter Executive's "at will" employment status.

2

		
	c.
	A "Change in Control” shall be deemed to have occurred if:

		
	(i)
	any Person (other than (w) the Company, (x) any trustee or other fiduciary holding securities under any employee benefit plan of the Company, (y) any company owned, directly or indirectly, by the stockholders of the Company immediately after the occurrence with respect to which the evaluation is being made in substantially the same proportions as their ownership of the common stock of the Company immediately prior to such occurrence or (z) any surviving or resulting entity from a merger or consolidation referred to in clause (iii) below that does not constitute a Change in Control under clause (iii) below) becomes the Beneficial Owner (except that a Person shall be deemed to be the Beneficial Owner of all shares that any such Person has the right to acquire pursuant to any agreement or arrangement or upon exercise of conversion rights, warrants or options or otherwise, without regard to the sixty day period referred to in Rule 13d-3 under the Exchange Act), directly or indirectly, of securities of the Company or of any subsidiary owning directly or indirectly all or substantially all of the consolidated assets of the Company (a "Significant Subsidiary"), representing 30% or more of the combined voting power of the Company's or such Significant Subsidiary's then outstanding securities;

		
	(ii)
	during any period of twelve (12) consecutive months, individuals who at the beginning of such period constitute the Board, and any new director whose election by the Board or nomination for election by the Company's stockholders was approved by a vote of at  least a majority of the directors then still in office who either were directors at the beginning of the twelve (12) month period or whose election or nomination for election was previously so approved, cease for  any reason to constitute at least a majority of the Board;

		
	(iii)
	the consummation of a merger or consolidation of the Company or any Significant Subsidiary with any other entity, other than a merger or consolidation which would result in the voting securities of the Company or a Significant Subsidiary outstanding immediately prior thereto continuing to represent (either by remaining outstanding or by being converted into voting securities of the surviving or resulting entity) more than 50% of the combined voting power of the surviving or resulting entity outstanding immediately after such merger or consolidation; or

		
	(iv)
	the consummation of a transaction (or series of transactions within a 12 month period) which constitutes the sale or disposition of all or substantially all of the consolidated assets of the Company but in no event assets having a gross fair market value of less than 40% of the total gross fair market value of all of the consolidated assets of the Company (other than such a sale or disposition immediately after which such assets will be owned directly or indirectly by the stockholders of the Company in substantially the same proportions as their ownership of the common stock of the Company immediately prior to such sale or disposition)

For purposes of this definition:

		
	(A)
	The term "Beneficial Owner" shall have the meaning ascribed to such term in Rule 13d-3 under the Exchange Act (including

 3

		
	   
	any successor to such Rule).

(B) The term "Exchange Act" means the Securities Exchange Act of 1934, as amended from time to time, or any successor act thereto.

(C) The term "Person" shall have the meaning ascribed to such term in Section 3(a)(9) of the Exchange Act and used in Sections 13(d) and 14(d) thereof, including "group" as defined in Section 13(d) thereof.

		
	d.
	"Committee" shall mean the Management Planning and Development Committee of the Board, or the corresponding committee of the board of directors of a successor to CVS Caremark.

		
	e.
	"Company" shall mean, collectively, CVS Caremark and any Subsidiary or affiliate of CVS Caremark.

		
	f.
	"Confidential Information" shall have the meaning set forth in Section 4 below.

		
	g.
	"Constructive Termination Without Cause" shall mean a termination of the Executive's employment at Executive's initiative following the occurrence, without the Executive's written consent, of one or more of the following events (except as a result of a prior termination):

		
	i.
	an assignment of any duties to Executive that is inconsistent with Executive's status as a member of the senior management of CVS Caremark;

		
	ii.
	a material decrease in Executive's annual base salary or target annual incentive award opportunity;

		
	iii.
	any failure to secure the agreement of any successor to CVS Caremark to fully assume the Company's obligations under this Agreement; or

		
	iv.
	a relocation of Executive's principal place of employment more than 35 miles from Executive's place of employment before such relocation.

		
	h.
	"Disability" shall mean disability as that term is defined in the Company's Long-Term Disability Plan.

		
	i.
	"Effective Date" shall have the meaning set forth in Section 2 below.

		
	j.
	"Original Term" shall have the meaning set forth in Section 2 below.

		
	k.
	"Renewal Term" shall have the meaning set forth in Section 2 below.

		
	I.
	"Severance Period" shall mean the period of 18 months following the termination of Executive's employment with the Company.

		
	m.
	"Subsidiary" shall have the meaning set forth in Section 4 below.

		
	n.
	"Term" shall have the meaning set forth in Section 2 below.

		
	o .
	"termination of employment", "employment is terminated" and other similar words shall mean with respect to Executive:

4

(i)    for any plan or arrangement that is subject to the rules of Section 409A of the Internal Revenue Code (the "Code") a "Separation from Service" as such term is defined in the Income Tax Regulations under Section 409A (the "409A Regulations") of the Code as modified by the rules described below:

		
	(A)
	except in the case where Executive is on a bona fide leave of absence pursuant to the Company's policies as provided below, Executive is deemed to have incurred a Separation from Service on a date if the company and Executive reasonably anticipate that the level of services to be performed by Executive after such date would be permanently reduced to 20% or less of the average services rendered by Executive during the immediately preceding 36-month period (or the total period of employment, if less than 36 months), disregarding periods during which Executive was on a bona fide leave of absence;

		
	(B)
	if Executive is absent from work due to military leave, sick leave, or other bona fide leave of absence pursuant to the Company's  policies, Executive shall incur a Separation from Service on the first date that the rules of (A), above, are satisfied following the later of (i) the six-month anniversary of the commencement of the leave or (ii) the expiration of Executive's right, if any, to reemployment under statute, contract or Company policy;

		
	(C)
	Executive shall be considered to continue employment and to not have a Separation from Service while on a bona fide leave of absence pursuant to the Company's policies if the leave does not exceed 6 consecutive months (12) months for a disability leave of absence) or, if longer, so long as the Executive retains a right to reemployment with the Company or an Affiliate under an applicable statute, contract or Company policy. For this purpose, a "disability leave of absence" is an absence due to any medically determinable physical or mental impairment of Executive that can be expected to result in death or can be expected to last for a continuous period of not less than 6 months, where such impairment causes the Participant to be unable to perform the duties of his job or a substantially similar job;

		
	(D)
	for purposes of determining whether another organization is an Affiliate of the Company, common ownership of at least 50% shall be determinative;

		
	(E)
	the Company specifically reserves the right to determine whether a sale or other disposition of substantial assets to an unrelated party constitutes a Separation from Service with respect to Executive providing services to the seller immediately prior to the transaction and providing services to the buyer after the transaction. Such determination shall be made in accordance with the requirements of Section 409A of the Code; or

		
	(ii)
	for any plan or arrangement that is not subject to the rules of Section 409A of the Code, the complete cessation of providing service to the Company or any Affiliate as an employee.

5

		
	2.
	Term of Agreement.

The term of this Agreement shall commence on the date of this Agreement (the "Effective Date") and end on the third anniversary of such date (the "Original Term"). The Original Term shall be automatically renewed for successive one-year terms (the "Renewal Terms") unless at least 180 days prior to the expiration of the Original Term or any Renewal Term, either Party notifies the other Party in writing that he/she or it is electing to terminate this Agreement at the expiration of the then current Term. "Term" shall mean the Original Term and all Renewal Terms. If a Change in Control shall have occurred during the Term, notwithstanding any other provision of this Section 2, the Term shall not expire earlier than two years after such Change in Control.

		
	3.
	Entitlement to Severance Benefit.

		
	a.
	Severance Benefit. In the event Executive's employment with the Company is Terminated Without Cause, other than due to death, or Disability, or in the event there is

a Constructive Termination Without Cause within two years following a Change in Control, Executive shall be entitled to receive:

		
	i.
	Base Salary through the date of termination of Executive's employment, which shall be paid in a cash lump sum not later than 15 days following Executive's termination of employment;

		
	ii.
	An amount equal to 1.5 times Executive's Base Salary in effect on the date of termination of Executive's employment (or in the event a reduction in Base Salary is a basis for a Constructive Termination Without Cause, then the Base Salary in effect immediately prior to such reduction), payable in a cash lump sum promptly (but in no event later than 15 days) following Executive's termination of employment;

		
	iii.
	An amount equal to the sum of (A) the most recently established target annual cash incentive bonus amount, pro rated based on the portion of the performance year that Executive has worked as of the date of Executive's termination, plus

		
	(B)
	25% of Base Salary (which represents an amount equal to the cash value of

the target annual Performance-Based Restricted Stock unit award for the year in which termination occurs), pro rated based on the portion of the performance year that Executive has worked as of the date of his/her termination. The Base Salary will be determined in accordance with Section 3.a.ii. Such payment of a pro rata annual cash incentive bonus and cash in lieu of Performance-Based Restricted Stock will be payable in a cash lump sum promptly (but in no event later than 15 days) following Executive's termination of employment;

		
	iv.
	An amount equal to 1.5 times the sum of (A) the most recently established target annual incentive cash bonus amount plus (B) 25% of Base Salary (determined in accordance with Section 3.a.ii above), payable in a cash lump sum promptly {but in no event later than 15 days) following the Executive's termination of employment;

		
	v.
	Elimination of all restrictions on any restricted stock or restricted stock unit awards outstanding at the time of termination of employment (other than awards under the Company's Partnership Equity Program, which shall be governed by the terms of such awards);

		
	vi.
	Immediate vesting of all outstanding stock options and the right to exercise such stock options for the remainder of the full term of such option (other than awards

6

under the Company's Partnership Equity Program, which shall be governed by the terms of such awards);

		
	vii.
	The balance of any incentive awards earned as of December 31 of the prior year (but not yet paid), which shall be paid in a single lump sum not later than 15 days following Executive's termination of employment;

		
	viii.
	Settlement of all deferred compensation arrangements in accordance with any then applicable deferred compensation plan or election form;

		
	ix.
	Continued participation in all medical, health and life insurance plans at the same benefit level at which Executive was participating on the date of termination of Executive's employment until the earlier of:

		
	1.
	the end of the Severance Period; or

		
	2.
	the date, or dates, Executive receives equivalent coverage and benefits under the plans and programs of a subsequent employer (such coverage and benefits to be determined on a coverage-by­ coverage, or benefit-by-benefit, basis);

provided that (1) if Executive is precluded from continuing Executive's participation in any employee benefit plan or program as provided in this clause (ix) of this Section 3.a, Executive shall receive cash payments equal on an after­ tax basis to the cost to Executive of obtaining the benefits provided under the plan or program in which Executive is unable to participate for the period specified in this clause (ix) of this Section 3.a, (2) such cost shall be deemed to be the lowest reasonable cost that would be incurred by Executive in obtaining such benefit on an individual basis, and (3) payment of such amounts shall be made quarterly in advance; and

		
	x.
	other or additional benefits then due or earned in accordance with applicable plans and programs of the Company.

		
	b.
	Change in Control Best Payments Determination. In the event the Severance Benefits described in Section 3(a) are payable to Executive in connection with a Change in Control and, if paid, could subject Executive to an excise tax under Section 4999 of the Internal Revenue Code (the "Excise Tax"), then notwithstanding the provisions of Section 3(a) the Company shall reduce the Severance Benefits (the "Benefit Reduction") under Section 3(a) by the amount necessary to result in the Executive not being subject to the Excise Tax if such reduction would result in the Executive's "Net After-Tax Amount" attributable to the Severance Benefits described in Section 3(a) being greater than it would be if no Benefit Reduction was effected. For this purpose "Net After-Tax Amount" shall mean the net amount of Severance Benefits Executive is entitled to receive under this Agreement after giving effect to all Federal, state and local taxes which would be applicable to such payments, including, but not limited to, the Excise Tax. The determination of whether any such Benefit Reduction shall be effected shall be made by a nationally recognized public accounting firm selected by the Company (the "Accounting Firm") prior to the occurrence of the Change in Control and such determination shall be binding on both Executive and the Company. In the event it is determined that a Benefit Reduction is required, such reduction of items described in Section 3(a) above shall be done first by reducing cash severance determined in accordance with Section 3(a)(ii), 3(a)(iii) and 3(a)(iv); to the extent a further Benefit Reduction is necessary, then Severance Benefits will be reduced from the amounts determined in accordance with Section 3(a)(v) and 3(a)(vi), all as determined by the Accounting Firm.

7

		
	c.
	No Mitigation; No Offset. In the event of any termination of employment under this Section 3, Executive shall be under no obligation to seek other employment, and the amounts due Executive under this Agreement shall not be offset by any remuneration attributable to any subsequent employment that Executive may obtain.

		
	d.
	Nature of Payments. Any amounts due under this Section 3 are in the nature of severance payments considered to be reasonable by the Company and are not in the nature of a penalty.

		
	e.
	Exclusivity of Severance Benefit.  Upon termination of Executive's employment following a Change in Control, Executive shall not be entitled to any severance payments or severance benefits from the Company, or any other payments by the Company pursuant to any other agreement or arrangement between Executive and the Company, other than the Severance Benefit provided in this Section 3, except as required by law.

		
	f.
	General Release of Claims. Executive agrees, as a condition of payment of the Severance Benefit provided for in this Section 3, that Executive will execute within 60 days of Executive's termination of employment a separation agreement, in a form reasonably satisfactory to the Company, that includes a general release of any and all claims arising out of Executive’s employment or termination of employment with the Company, other than claims for (i) enforcement of this Agreement, (ii) enforcement of Executive's rights under any of the Company's incentive compensation, equity and/or employee benefit plans and programs to which Executive is entitled under this Agreement, and (iii) any tort for personal injury not arising out of or related to Executive's employment or termination of employment.

		
	g.
	Subject to the provisions of Section 13(b), all payments to be made pursuant to this Section 3 upon the termination of employment of Executive shall be made or commence, as the case may be, within 75 days after the Executive's termination of employment provided, however, that if such termination of employment is after October 15 of a year, the payment or first payment, as the case may be, shall be made at the end of such 75 day period.

		
	4.
	Confidentiality; Cooperation with Regard to Litigation: Non-disparagement.

		
	a.
	During the Term and thereafter, Executive shall not, without the prior written consent of the Company, disclose to anyone (except in good faith in the ordinary course of business to a person who will be advised by Executive to keep such information confidential) or make use of any confidential information except in the performance of Executive's duties hereunder or when required to do so by legal process, by any governmental agency having supervisory authority over the business of the Company or by any administrative or legislative body (including a committee thereof) that requires Executive to divulge, disclose or make accessible such information. In the event that Executive is so ordered, Executive shall give prompt written notice to the Company in order to allow the Company the opportunity to object to or otherwise resist such order.

		
	b.
	During the Term and thereafter, Executive shall not disclose the existence or contents of this Agreement beyond what is disclosed in the proxy statement or documents filed with the government unless and to the extent such disclosure is required by law, by a governmental agency, or in a document required by law to be filed with a governmental agency or in connection with enforcement of his/her rights under this Agreement. In the event that disclosure is so required, Executive shall give prompt written notice to the Company in order to allow the Company the opportunity to object to or otherwise resist such requirement. This restriction shall not apply to such disclosure by Executive to members of his/her immediate family, his/her tax, legal or financial advisors, any lender,

8

or tax authorities, or to potential future employers to the extent necessary, each of whom shall be advised not to disclose such information.

		
	c.
	"Confidential Information" shall mean all information concerning the business of the Company or any Subsidiary relating to any of their products, product development, trade secrets, customers, suppliers, finances, and  business plans and strategies. Excluded from the definition of Confidential Information is information (i) that is or becomes part of the public domain, other than through the breach of this Agreement by Executive or (ii) regarding the Company's business or industry properly acquired by Executive in the course of Executive's career as an Executive in the Company's industry and independent of Executive's employment by the Company. For this purpose, information known or available generally within the trade or industry of the Company or any Subsidiary shall be deemed to be known or available to the public.

		
	d.
	"Subsidiary" shall mean any corporation or other business entity owned or controlled directly or indirectly by CVS Caremark.

		
	e.
	Executive agrees to cooperate with the Company, during the Term and thereafter (including following Executive's termination of employment for any reason), by being reasonably available to testify on behalf of the Company or any Subsidiary in any action, suit, or proceeding, whether civil, criminal, administrative, or investigative, and to assist the Company, or any Subsidiary, in any such action, suit, or proceeding, by providing information and  meeting  and consulting with the Board or its representatives or counsel, or representatives or counsel to the Company, or any Subsidiary as requested; provided, however that the same does not materially interfere with Executive's then current professional activities. The Company agrees to reimburse Executive on an after tax basis, for all reasonable expenses actually incurred in connection with Executive's provision of testimony or assistance.

		
	f.
	Executive agrees that, during the Term and thereafter (including following Executive's termination of employment for any reason) Executive will not make statements or representations, or otherwise communicate, directly or indirectly, in writing, orally, or otherwise, or take any action which may, directly or indirectly, disparage or be damaging to the Company or any Subsidiary or their respective officers, directors, employees, advisors, businesses or reputations. Notwithstanding the foregoing, nothing in this Agreement shall preclude Executive from making truthful statements or disclosures that are required by applicable law, regulation or legal process.

		
	5.
	Non-solicitation.

During the period beginning with the Effective Date and ending 18 months following the termination of Executive's employment with the Company, Executive, whether acting on Executive's own behalf or by, through or on behalf of any third party, shall not (a) hire any employees of the Company or any Subsidiary, or recruit or solicit any such employees or encourage them to terminate their employment with the Company or any Subsidiary; (b) accept business from any customers of the Company or any Subsidiary, or solicit or encourage any customers, joint venture partners or investors of the Company or any Subsidiary to terminate or diminish their relationship with the Company or any Subsidiary or to violate any agreement with the Company or any Subsidiary. For purposes of subsection 5(a), an employee of the Company or any Subsidiary means any person who was employed by the Company or any Subsidiary within 180 days of such hiring, recruitment, solicitation or encouragement. Executive agrees to make any employer with whom Executive becomes employed during the 18-month period following Executive's termination with the Company aware of this non-solicitation obligation upon commencing employment with such subsequent entity.

9

		
	6.
	Remedies.

In addition to whatever other rights and remedies the Company may have at equity or in law, the Company (a) shall have the right to immediately terminate all payments and benefits due under this Agreement if Executive breaches any of the provisions contained in Sections 4 or 5 above, and (b) shall have the right to seek injunctive relief in any court of competent jurisdiction if Executive breaches or threatens to breach any of the provisions contained in Sections 4 or 5 above. Executive acknowledges that such a breach would cause irreparable injury and that money damages would not provide an adequate remedy for the Company; provided, however, the foregoing shall not prevent Executive from contesting the issuance of any such injunction on the ground that no violation or threatened violation of Sections 4 or 5 has occurred.

		
	7.
	Effect of Agreement on Other Benefits and Obligations.

Except as specifically provided in this Agreement, the existence of this Agreement shall not be interpreted to preclude, prohibit or restrict the Executive's participation in any other employee benefit or other plans or programs in which he /she currently participates. Except as specifically provided in this Agreement, the terms of Sections 4 and 5 of this Agreement shall not be deemed to restrict or supersede prior to a Change in Control any similar obligations Executive may have to the Company or its subsidiaries under any other agreement.

		
	8.
	Not an Employment Agreement.

This Agreement is not, and nothing herein shall be deemed to create, a contract of employment between Executive and the Company. The Company may terminate the employment of Executive at any time and for any reason, subject to the terms of any employment agreement between the Company and Executive that may then be in effect.

		
	9.
	Resolution of Disputes.

Any controversy or claim arising out of or relating to this Agreement or any breach or asserted breach hereof or questioning the validity and binding effect hereof arising under or in connection with this Agreement, other than seeking injunctive relief under Sections 4 or 5, shall be resolved by binding arbitration, to be held at an office closest to the Company's principal offices in accordance with the rules and procedures of the American Arbitration Association. Judgment upon the award rendered by the arbitrator(s) may be entered in any court having jurisdiction thereof. Pending the resolution of any arbitration or court proceeding, the company shall continue payment of all amounts and benefits due Executive under this Agreement. All reasonable costs and expenses of any arbitration or court proceeding (including fees and disbursements of counsel) shall be paid on behalf of or reimbursed to Executive promptly by the Company; provided, however, that no reimbursement shall be made of such expenses if and to the extent the arbitrator(s) determine(s) that any of Executive's litigation assertions or defenses were in bad faith or frivolous.

		
	10.
	Assignability; Binding Nature.

This Agreement shall be binding upon and inure to the benefit of the Parties and their respective successors, heirs (in the case of Executive) and permitted assigns. No rights or obligations of the Company under this Agreement may be assigned or transferred by the Company except that such rights or obligations may be assigned or transferred in connection with the sale or transfer of all or substantially all of the assets of the Company, provided that the assignee or  transferee  is the successor to all or substantially all of the assets of the Company and such assignee or transferee assumes the liabilities, obligations and duties of the Company, as contained in this agreement, either contractually or as a matter of law. The Company further agrees that, in the event of a sale or transfer of assets as described in the preceding sentence, it shall take whatever

10

action it legally can in order to cause such assignee or transferee to expressly assume the liabilities, obligations and duties of the Company hereunder. No rights or obligations of Executive under this Agreement may be assigned or transferred by Executive other than his/her, rights to compensation and benefits, which may be transferred only by will or operation of law, except as provided in Section 16 below.

		
	11.
	Representation.

The Company represents and warrants that it is fully authorized and empowered to enter into this Agreement and that the performance of its obligations under this Agreement will not violate any agreement between it and any other person, firm or organization.

		
	12.
	Entire Agreement.

This Agreement contains the entire understanding and agreement between the Parties concerning the parties' rights and obligations in connection with the subject matter of this Agreement in the event of a Change in Control and supersedes all prior agreements, understandings, discussions, negotiations and undertakings, whether written or oral, between the Parties with respect thereto.

		
	13.
	Amendment: Waiver; Code Section 409A.

		
	(a)
	No provision in this Agreement may be amended unless such amendment is agreed to in writing and signed by Executive and an authorized officer of the Company. No waiver by either Party of any breach by the other Party of any condition or provision contained in this Agreement to be performed by such other Party shall be deemed a waiver of a similar or dissimilar condition or provision at the same or any prior or subsequent time. Any waiver must be in writing and signed by Executive or an authorized officer of the Company, as the case may be.

		
	(b)
	Executive and Company agree that it is the intent of the parties that this Agreement not violate any applicable provision of, or result in any additional tax or penalty under, Section 409A of the Code, as amended, and that to the extent any provisions of this Agreement do not comply with such Code Section 409A the parties will make such changes as are mutually agreed upon in order to comply with Code Section 409A. In all events, to the extent required to avoid a violation of any of the applicable rules under Code Section 409A by reason of Code Section 409A(a)(2)(B)(i), payment of any amounts subject to Code Section 409A shall be delayed until the relevant date of payment that will result in compliance with the rules of Code Section 409A(a)(2)(B)(i).

		
	14.
	Severability.

In the event that any provision or portion of this Agreement shall be determined to be invalid or unenforceable for any reason, in whole or in part, the remaining provisions of this Agreement shall be unaffected thereby and shall remain in full force and effect to the fullest extent permitted by law.

		
	15.
	Survivorship.

The respective rights and obligations of the Parties hereunder shall survive any termination of Executive's employment to the extent necessary to the intended preservation of such rights and obligations.

11

		
	16.
	Beneficiaries/References.

Executive shall be entitled, to the extent permitted under any applicable law, to select and change a beneficiary or beneficiaries to receive any compensation or benefit payable hereunder following Executive's death by giving the Company written notice thereof. In the event of Executive's death or a judicial determination of Executive's incompetence, references in this Agreement to Executive shall be deemed, where appropriate, to refer to Executive's beneficiary, estate or other legal representative.

		
	17.
	Governing Law/Jurisdiction.

This Agreement shall be governed by and construed and interpreted in accordance with the laws of Rhode Island without reference to principles of conflict of laws. Subject to Section 6, the Company and Executive hereby consent to the jurisdiction of any or all of the following courts for purposes of resolving any dispute under this Agreement: (i) the United States District Court for Rhode Island or (ii) any of the courts of the State of Rhode Island. The Company and Executive further agree that any service of process or notice requirements in such proceeding shall be satisfied if the rules of such court relating thereto have been substantially satisfied. The Company and Executive hereby waive, to the fullest extent permitted by applicable law, any objection which
it or Executive may now or hereafter have to such jurisdiction and any defense of inconvenient forum.

		
	18.
	Notices.

Any notice given to a Party shall be in writing and shall be deemed to have been given when delivered personally or sent by certified or registered mail, postage prepaid, return receipt requested, duly addressed to the Party concerned at the address indicated below or to, such changed address as such Party may subsequently give such notice of:

lf to CVS:

CVS Pharmacy, Inc. 
One CVS Drive Woonsocket, RI 02895
Attention: Corporate Secretary 
If to Executive:

Eva Boratto
XXXXXXXXXXXXX
XXXXXXXXXXXXXXXXXX

		
	19.
	Headings.

The headings of the sections contained in this Agreement are for convenience only and shall not be deemed to control or affect the meaning or construction of any provision of this Agreement.

12

		
	20.
	Counterparts.

This Agreement may be executed in two or more counterparts.

In WITNESS WHEREOF, the undersigned have executed this Agreement to be effective as of the date first written above.

CVS Pharmacy, Inc.

By:
/s/ Lisa Bisaccia                                         
Name: Lisa Bisaccia
Title: SVP and Chief Human
Resources Officer
Date: 7/14/2010

Executive:
/s/ Eva Boratto                                             
Eva Boratto
SVP, Finance, PBM
Date:

13

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00295-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00295-of-00352.parquet"}]]